S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Urgent Warning (Ad)
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Roku And The 20% Rally That’s About To Start 
Urgent Warning (Ad)
Don't Be Fooled by These 3 Value Traps
The Bottom Is In For McCormick & Company
Urgent Warning (Ad)
3 Undervalued Dividend Payers For Volatile Market Conditions
Buffett's company owns nearly 24% of Occidental Petroleum
S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Urgent Warning (Ad)
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Roku And The 20% Rally That’s About To Start 
Urgent Warning (Ad)
Don't Be Fooled by These 3 Value Traps
The Bottom Is In For McCormick & Company
Urgent Warning (Ad)
3 Undervalued Dividend Payers For Volatile Market Conditions
Buffett's company owns nearly 24% of Occidental Petroleum
S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Urgent Warning (Ad)
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Roku And The 20% Rally That’s About To Start 
Urgent Warning (Ad)
Don't Be Fooled by These 3 Value Traps
The Bottom Is In For McCormick & Company
Urgent Warning (Ad)
3 Undervalued Dividend Payers For Volatile Market Conditions
Buffett's company owns nearly 24% of Occidental Petroleum
S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Urgent Warning (Ad)
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Roku And The 20% Rally That’s About To Start 
Urgent Warning (Ad)
Don't Be Fooled by These 3 Value Traps
The Bottom Is In For McCormick & Company
Urgent Warning (Ad)
3 Undervalued Dividend Payers For Volatile Market Conditions
Buffett's company owns nearly 24% of Occidental Petroleum
NASDAQ:RNA

Avidity Biosciences - RNA News Today

$20.09
+0.31 (+1.57%)
(As of 03/28/2023 12:00 AM ET)
Add
Compare
Today's Range
$19.68
$20.28
50-Day Range
$19.56
$25.65
52-Week Range
$9.83
$25.74
Volume
471,360 shs
Average Volume
1.07 million shs
Market Capitalization
$1.42 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$44.60
Get Avidity Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for RNA and its competitors with MarketBeat's FREE daily newsletter.


RNA Media Mentions By Week

RNA Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

RNA
News Sentiment

1.27

0.61

Average
Medical
News Sentiment

RNA News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

RNA Articles
This Week

2

1

RNA Articles
Average Week

SourceHeadline
MarketBeat logoAvidity Biosciences (NASDAQ:RNA) Shares Down 3.6%
americanbankingnews.com - March 24 at 8:48 AM
finance.yahoo.com logoAvidity Biosciences Announces Upcoming Presentations at 2023 MDA Clinical & Scientific Conference
finance.yahoo.com - March 13 at 7:41 PM
seekingalpha.com logoAvidity Biosciences: Helping Deliver Oligonucleotides Outside Liver Cells
seekingalpha.com - March 11 at 5:21 PM
markets.businessinsider.com logoAvidity Biosciences (RNA) Receives a Buy from Credit Suisse
markets.businessinsider.com - March 1 at 2:32 PM
finanznachrichten.de logoAvidity Biosciences, Inc.: Avidity Biosciences Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Highlights
finanznachrichten.de - March 1 at 9:31 AM
finance.yahoo.com logoAvidity Biosciences Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Highlights
finance.yahoo.com - March 1 at 9:31 AM
finance.yahoo.com logoAvidity Biosciences, Inc. (RNA) Reports Q4 Loss, Tops Revenue Estimates
finance.yahoo.com - March 1 at 9:31 AM
finance.yahoo.com logoAnalyst Says This Small Cap Biotech Firm Has 'Very Valuable Therapeutic,' Upgrades Stock
finance.yahoo.com - February 27 at 5:05 PM
finance.yahoo.com logoAvidity Advances RNA Programs and Expands into New Therapeutic Areas Utilizing its AOC™ Platform
finance.yahoo.com - February 27 at 10:55 AM
finance.yahoo.com logoAvidity Biosciences Announces Arthur A. Levin to Join Board of Directors and Transition to Distinguished Scientist and Strategic Leader
finance.yahoo.com - February 23 at 9:08 AM
markets.businessinsider.com logoAvidity's AOC 1020 Gets FDA Orphan Drug Designation For Muscular Dystrophy Treatment
markets.businessinsider.com - February 14 at 1:36 PM
marketwatch.com logoAvidity Biosciences Gets FDA Orphan Designation for AOC 1020 >RNA
marketwatch.com - February 14 at 1:36 PM
finance.yahoo.com logoAvidity Biosciences Receives FDA Orphan Drug Designation for AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy
finance.yahoo.com - February 14 at 1:36 PM
finance.yahoo.com logoAvidity Biosciences to Participate in Upcoming Investor Conference
finance.yahoo.com - February 7 at 9:16 AM
finance.yahoo.com logoThe one-year returns have been notable for Avidity Biosciences (NASDAQ:RNA) shareholders despite underlying losses increasing
finance.yahoo.com - February 2 at 10:19 AM
msn.com logoAvidity's therapy for rare muscle disorder gets FDA fast track status
msn.com - January 18 at 2:54 PM
finance.yahoo.com logoAvidity Biosciences Granted FDA Fast Track Designation for AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy
finance.yahoo.com - January 18 at 9:54 AM
msn.com logoPeering Into Avidity Biosciences's Recent Short Interest
msn.com - January 3 at 1:26 PM
seekingalpha.com logoAvidity Biosciences Will Rise As It Revolutionizes The Field Of RNA Therapeutics
seekingalpha.com - December 23 at 8:30 AM
finance.yahoo.com logoFollowing a 16% decline over last year, recent gains may please Avidity Biosciences, Inc. (NASDAQ:RNA) institutional owners
finance.yahoo.com - December 23 at 8:30 AM
seekingalpha.com logoAvidity Biosciences: Unique Antibody-Oligonucleotide Conjugate Technology
seekingalpha.com - December 22 at 6:55 AM
seekingalpha.com logoAvidity Biosciences: Proof-Of-Concept Achieved In DM1 For AOC Platform
seekingalpha.com - December 21 at 6:49 AM
msn.com logoThis Genetic Medicine Stock Soared Over 50% on Industry First
msn.com - December 15 at 3:21 PM
finance.yahoo.com logoThis Genetic Medicine Stock Soars Over 50% on Industry First
finance.yahoo.com - December 14 at 11:37 PM
finance.yahoo.com logoAvidity Biosciences Shares Gain On Encouraging Data From Early-Stage Myotonic Dystrophy Trial
finance.yahoo.com - December 14 at 6:37 PM
markets.businessinsider.com logoExpert Ratings for Avidity Biosciences
markets.businessinsider.com - December 14 at 6:37 PM
finance.yahoo.com logoHow A First-Ever In Gene Silencing Catapulted Avidity Biosciences Into The Stratosphere
finance.yahoo.com - December 14 at 1:36 PM
markets.businessinsider.com logoAvidity Reports Effective Delivery Of SiRNA Into Muscle; Shows Meaningful DMPK Reduction
markets.businessinsider.com - December 14 at 8:36 AM
finance.yahoo.com logoAvidity Announces Positive AOC 1001 Phase 1/2 MARINA™ Data Demonstrating First-Ever Successful Targeted Delivery of RNA to Muscle - Revolutionary Advancement for the Field of RNA Therapeutics
finance.yahoo.com - December 14 at 8:36 AM
finance.yahoo.com logoAvidity's stock rallies 39% on new RNA data
finance.yahoo.com - December 14 at 8:36 AM
marketwatch.com logoRNA Sequencing Analysis Market : Competitive Landscape and Analysis by Recent Trends 2023 to 2028
marketwatch.com - December 13 at 6:16 AM
finance.yahoo.com logoDown 15.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Avidity Biosciences, Inc. (RNA)
finance.yahoo.com - November 18 at 1:29 PM
finance.yahoo.com logoAvidity Biosciences Third Quarter 2022 Earnings: Beats Expectations
finance.yahoo.com - November 11 at 9:47 AM
finance.yahoo.com logoAvidity Biosciences Reports Third Quarter 2022 Financial Results and Recent Highlights
finance.yahoo.com - November 8 at 4:23 PM
finance.yahoo.com logoAvidity Biosciences Announces Phase 1/2 EXPLORE44™ Trial of AOC 1044 for Duchenne Muscular Dystrophy Mutations Amenable to Exon 44 Skipping
finance.yahoo.com - October 11 at 9:02 PM
benzinga.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avidity Biosciences, Inc. - RNA
benzinga.com - October 6 at 7:15 PM
finance.yahoo.com logoAvidity Biosciences Announces Upcoming Presentations at 27th International Hybrid Annual Congress of World Muscle Society
finance.yahoo.com - October 6 at 2:15 PM
finance.yahoo.com logoAvidity Biosciences Announces the Phase 1/2 FORTITUDE™ Trial of AOC 1020 in Adults with Facioscapulohumeral Muscular Dystrophy
finance.yahoo.com - September 29 at 10:23 AM
msn.com logoU.S. FDA puts Avidity's muscle disorder drug trial on partial hold
msn.com - September 28 at 2:57 AM
finance.yahoo.com logoFDA Slaps Clinical Hold On Avidity's Early-Stage Myotonic Dystrophy Trial
finance.yahoo.com - September 27 at 4:56 PM
nasdaq.com logoAvidity: FDA Places Partial Clinical Hold On Participant Enrollment In Phase 1/2 MARINA Trial
nasdaq.com - September 27 at 11:55 AM
msn.com logoTwitter, JetBlue, Lucid Group Rise Premarket; Avidity, Ferguson Fall
msn.com - September 27 at 11:55 AM
msn.com logoU.S. FDA puts Avidity's muscle disorder drug study on hold
msn.com - September 27 at 11:55 AM
marketwatch.com logoAvidity Biosciences: FDA Places Partial Hold on AOC 1001 Study >RNA
marketwatch.com - September 27 at 11:55 AM
marketwatch.com logoAvidity Biosciences Shares Slide on Partial FDA Study Hold >RNA
marketwatch.com - September 27 at 11:55 AM
finance.yahoo.com logoAvidity Biosciences Announces FDA Partial Clinical Hold on New Participant Enrollment in Phase 1/2 MARINA™ Trial
finance.yahoo.com - September 27 at 11:55 AM
finance.yahoo.com logoAvidity shares fall 23% after announcing partial clinical hold for myotonic dystrophy trial
finance.yahoo.com - September 27 at 11:55 AM
finance.yahoo.com logoHighly Rated Avidity Biosciences Hammered After Side Effect Sidelines Study
finance.yahoo.com - September 27 at 11:55 AM
finance.yahoo.com logoAvidity Biosciences Engages with Patient Communities During National Muscular Dystrophy Awareness Month as part of Commitment to Developing Muscular Dystrophy Programs
finance.yahoo.com - September 7 at 8:11 AM
nasdaq.com logoThe one-year returns have been for Avidity Biosciences (NASDAQ:RNA) shareholders despite underlying losses increasing
nasdaq.com - August 20 at 11:12 PM
Get Avidity Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for RNA and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:RNA) was last updated on 3/29/2023 by MarketBeat.com Staff